Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized liposomal amphotericin B for prophylaxis of invasive pulmonary aspergillosis in acute myeloid leukemia and allogeneic hematopoietic progenitor transplant
2005-000703-34Phase 2Active
- Sponsor
- Fundación PETHEMA
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of amphotericin b in Acute Invasive Aspergillosis (2 cohorts), sponsored by Fundación PETHEMA. Primary endpoints: Tolerability of nebulized liposomal amphotericin B, Safety of nebulized liposomal amphotericin B and 1 more. Started Jun 2005; status: active.
02
Drugs
amphotericin b
03
Conditions
Acute Invasive Aspergillosis
Beyond the preview
Go deeper on 2005-000703-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000703-34.